688176 亚虹医药-U
已收盘 05-20 15:00:00
资讯
新帖
简况
亚虹医药（688176）披露2025年年度股东会会议资料，5月20日股价下跌0.32%
证券之星 · 59分钟前
亚虹医药（688176）披露2025年年度股东会会议资料，5月20日股价下跌0.32%
每周股票复盘：亚虹医药（688176）希维她商业化推进及海外临床进展
证券之星 · 05-17
每周股票复盘：亚虹医药（688176）希维她商业化推进及海外临床进展
股市必读：亚虹医药（688176）5月11日披露最新机构调研信息
证券之星 · 05-12
股市必读：亚虹医药（688176）5月11日披露最新机构调研信息
亚虹医药：5月11日召开业绩说明会
证券之星 · 05-11
亚虹医药：5月11日召开业绩说明会
每周股票复盘：亚虹医药（688176）将召开2025年年度股东会
证券之星 · 05-10
每周股票复盘：亚虹医药（688176）将召开2025年年度股东会
图解亚虹医药一季报：第一季度单季净利润同比下降34.56%
证券之星 · 04-29
图解亚虹医药一季报：第一季度单季净利润同比下降34.56%
亚虹医药(688176)3月31日股东户数2.63万户，较上期增加9.18%
证券之星 · 04-29
亚虹医药(688176)3月31日股东户数2.63万户，较上期增加9.18%
股市必读：亚虹医药年报 - 第四季度单季净利润同比下降47.88%
证券之星 · 04-20
股市必读：亚虹医药年报 - 第四季度单季净利润同比下降47.88%
每周股票复盘：亚虹医药（688176）股东户数增9.18%，营收增37.49%
证券之星 · 04-19
每周股票复盘：亚虹医药（688176）股东户数增9.18%，营收增37.49%
亚虹医药2025年净利亏损4.16亿元
北京商报 · 04-17
亚虹医药2025年净利亏损4.16亿元
每周股票复盘：亚虹医药（688176）非独立董事李显显因个人原因辞任
证券之星 · 03-29
每周股票复盘：亚虹医药（688176）非独立董事李显显因个人原因辞任
亚虹医药（688176）披露公司非独立董事辞任公告，3月27日股价上涨5.75%
证券之星 · 03-27
亚虹医药（688176）披露公司非独立董事辞任公告，3月27日股价上涨5.75%
3月23日亚虹医药跌9.43%，中航优选领航混合发起A基金重仓该股
证券之星 · 03-23
3月23日亚虹医药跌9.43%，中航优选领航混合发起A基金重仓该股
亚虹医药跌9.43%，太平洋五日前给出“买入”评级，目标价17.91元
证券之星 · 03-23
亚虹医药跌9.43%，太平洋五日前给出“买入”评级，目标价17.91元
3月12日亚虹医药跌5.67%，中航优选领航混合发起A基金重仓该股
证券之星 · 03-12
3月12日亚虹医药跌5.67%，中航优选领航混合发起A基金重仓该股
华鑫证券：给予亚虹医药买入评级
证券之星 · 03-11
华鑫证券：给予亚虹医药买入评级
3月9日亚虹医药涨5.24%，中航优选领航混合发起A基金重仓该股
证券之星 · 03-09
3月9日亚虹医药涨5.24%，中航优选领航混合发起A基金重仓该股
亚虹医药(688176.SH)：希维她®相关生产、进口时间及程序存在不确定性
智通财经 · 03-06
亚虹医药(688176.SH)：希维她®相关生产、进口时间及程序存在不确定性
3月6日亚虹医药（688176）龙虎榜数据：北向资金净买入2557.14万元
证券之星 · 03-06
3月6日亚虹医药（688176）龙虎榜数据：北向资金净买入2557.14万元
异动快报：亚虹医药-U（688176）3月6日10点7分触及涨停板
证券之星 · 03-06
异动快报：亚虹医药-U（688176）3月6日10点7分触及涨停板
加载更多
公司概况
公司名称：
江苏亚虹医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-07
主营业务：
江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域专科创新药的研发、生产和销售。公司的主要产品是APL-1702(希维她®)、APL-2302、APL-2501、AT-018、AT-021、APL-1706(海克威®)、APLD-2304、APL-1202、APL-2401、APL-1202、APL-1401、APL-2301。
发行价格：
22.98
{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药-U","latestPrice":12.6,"timestamp":1779260400000,"preClose":12.64,"halted":0,"volume":9639986,"delay":0,"changeRate":-0.0032,"floatShares":436000000,"shares":571000000,"eps":-0.7796,"marketStatus":"已收盘","change":-0.04,"latestTime":"05-20 15:00:00","open":12.65,"high":12.9,"low":12.52,"amount":122000000,"amplitude":0.0301,"askPrice":12.61,"askSize":60,"bidPrice":12.6,"bidSize":144,"shortable":0,"etf":0,"ttmEps":-0.7796,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779327000000},"marketStatusCode":5,"adr":0,"adjPreClose":12.64,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779240600000,1779247800000],[1779253200000,1779260400000]],"highLimit":13.9,"lowLimit":11.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":571170486,"isCdr":false,"pbRate":4.91,"roa":"--","roe":"--","epsLYR":-0.74,"committee":0.114644,"marketValue":7197000000,"turnoverRate":0.0221,"status":1,"afterMarket":{"amount":0,"volume":0,"close":12.6,"buyVolume":0,"sellVolume":0,"time":1779262437558,"indexStatus":"已收盘 05-20 15:30:00","preClose":12.64},"floatMarketCap":5490000000},"requestUrl":"/m/hq/s/688176","defaultTab":"news","newsList":[{"id":"2636825356","title":"亚虹医药（688176）披露2025年年度股东会会议资料，5月20日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636825356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636825356?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:31","pubTimestamp":1779287477,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，亚虹医药报收于12.6元，较前一交易日下跌0.32%，最新总市值为71.97亿元。该股当日开盘12.65元，最高12.9元，最低12.52元，成交额达1.22亿元，换手率为2.21%。近日，江苏亚虹医药科技股份有限公司发布2025年年度股东会会议资料。公司2025年度未盈利，拟不进行利润分配。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636062486","title":"每周股票复盘：亚虹医药（688176）希维她商业化推进及海外临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2636062486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636062486?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:47","pubTimestamp":1778964429,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，亚虹医药报收于12.51元，较上周的12.98元下跌3.62%。本周，亚虹医药5月11日盘中最高价报13.3元。本周关注点来自机构调研要点：希维她?已获批上市，商业化准备工作已启动，生产和进口相关工作正积极推进。上市许可申请已获欧洲药品管理局受理，正寻求海外商业化合作。公司3月3日即已获批，3月24日即已与上药科园贸易签署分销协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634306239","title":"股市必读：亚虹医药（688176）5月11日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634306239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634306239?lang=zh_cn&edition=full","pubTime":"2026-05-12 01:28","pubTimestamp":1778520489,"startTime":"0","endTime":"0","summary":"截至2026年5月11日收盘，亚虹医药报收于13.17元，上涨1.46%，换手率3.09%，成交量13.48万手，成交额1.75亿元。机构调研要点5月11日举行业绩说明会，主要内容如下：公司介绍了企业情况、主要业务进展及未来发展规划。海克威方面，合作伙伴R.WOLF的蓝光膀胱镜系统SYSTEMBLUE已获NMP批准上市，诊疗方案具备临床落地基础。后续进展公司将依规履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200001395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284926","title":"亚虹医药：5月11日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634284926?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:05","pubTimestamp":1778504712,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月11日亚虹医药发布公告称公司于2026年5月11日召开业绩说明会。公司3月3日即已获批，3月24日即已与上药科园贸易签署分销协议。亚虹医药2026年一季报显示，一季度公司主营收入7108.59万元，同比上升16.34%；归母净利润-1.12亿元，同比下降34.56%；扣非净利润-1.16亿元，同比下降30.06%；负债率27.26%，投资收益131.64万元，财务费用310.64万元，毛利率72.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100034096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634342414","title":"每周股票复盘：亚虹医药（688176）将召开2025年年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2634342414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634342414?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:15","pubTimestamp":1778350514,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，亚虹医药报收于12.98元，较上周的12.86元上涨0.93%。本周关注点公司公告汇总：江苏亚虹医药科技股份有限公司将于2026年5月27日召开2025年年度股东会。公司公告汇总江苏亚虹医药科技股份有限公司将于2026年5月27日召开2025年年度股东会，会议采取现场投票与网络投票相结合的方式，网络投票通过上海证券交易所系统进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631851620","title":"图解亚虹医药一季报：第一季度单季净利润同比下降34.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631851620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631851620?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:58","pubTimestamp":1777463909,"startTime":"0","endTime":"0","summary":"证券之星消息，亚虹医药2026年一季报显示，一季度公司主营收入7108.59万元，同比上升16.34%；归母净利润-1.12亿元，同比下降34.56%；扣非净利润-1.16亿元，同比下降30.06%；负债率27.26%，投资收益131.64万元，财务费用310.64万元，毛利率72.56%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900061051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631372596","title":"亚虹医药(688176)3月31日股东户数2.63万户，较上期增加9.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631372596","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631372596?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:42","pubTimestamp":1777455767,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亚虹医药披露，截至2026年3月31日公司股东户数为2.63万户，较12月31日增加2210.0户，增幅为9.18%。在化学制药行业个股中，亚虹医药股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.6万户。从股价来看，2025年12月31日至2026年3月31日，亚虹医药区间涨幅为13.64%，在此期间股东户数增加2210.0户，增幅为9.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900055372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628798027","title":"股市必读：亚虹医药年报 - 第四季度单季净利润同比下降47.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628798027","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628798027?lang=zh_cn&edition=full","pubTime":"2026-04-20 02:11","pubTimestamp":1776622268,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，亚虹医药报收于13.88元，下跌2.32%，换手率3.29%，成交量14.35万手，成交额2.0亿元。股本股东变化股东户数变动近日亚虹医药披露，截至2026年3月31日公司股东户数为2.63万户，较12月31日增加2210.0户，增幅为9.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000000935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628975625","title":"每周股票复盘：亚虹医药（688176）股东户数增9.18%，营收增37.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628975625","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628975625?lang=zh_cn&edition=full","pubTime":"2026-04-19 02:00","pubTimestamp":1776535238,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，亚虹医药报收于13.88元，较上周的13.99元下跌0.79%。本周，亚虹医药4月15日盘中最高价报14.59元。股本股东变化截至2026年3月31日，公司股东户数为2.63万户，较2025年12月31日增加2210户，增幅9.18%。户均持股数量由上期的2.37万股下降至2.17万股，户均持股市值为28.42万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628045052","title":"亚虹医药2025年净利亏损4.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628045052","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628045052?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:48","pubTimestamp":1776430080,"startTime":"0","endTime":"0","summary":"北京商报讯 4月17日晚间，亚虹医药发布2025年年报显示，公司2025年实现营业收入2.77亿元，同比增长37.49%；归属净利润为-4.16亿元。 亚虹医药表示，公司自设立以来即从事新药研发活动，该类项目研发周期长，需要在临床前研究、临床开发、产品生产与控制等方面投入大量资金。报告期内，公司持续专注于泌尿生殖系统肿瘤及女性健康领域的研发，各项新药研发项目持续推进，优秀人才不断加入，现金流情况良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-17/doc-inhuvkxa0928028.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-17/doc-inhuvkxa0928028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623380282","title":"每周股票复盘：亚虹医药（688176）非独立董事李显显因个人原因辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2623380282","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623380282?lang=zh_cn&edition=full","pubTime":"2026-03-29 02:37","pubTimestamp":1774723028,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，亚虹医药报收于13.6元，较上周的13.68元下跌0.58%。本周，亚虹医药3月27日盘中最高价报13.83元。本周关注点公司公告汇总：非独立董事李显显因个人原因申请辞任，离任后不再担任公司任何职务公司公告汇总江苏亚虹医药科技股份有限公司董事会于2026年3月27日收到非独立董事李显显先生的《辞任报告》，因个人原因申请辞去董事职务，离任后不再担任公司任何职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820470","title":"亚虹医药（688176）披露公司非独立董事辞任公告，3月27日股价上涨5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820470","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622820470?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:15","pubTimestamp":1774620919,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，亚虹医药报收于13.6元，较前一交易日上涨5.75%，最新总市值为77.68亿元。近日，江苏亚虹医药科技股份有限公司发布《关于公司非独立董事辞任的公告》。公告显示，公司董事会于2026年3月27日收到非独立董事李显显先生的《辞任报告》，因个人原因申请辞去董事职务，离任后不再担任公司任何职务。截至公告日，李显显先生未持有公司股份，不存在未履行完毕的公开承诺事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700049695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621768117","title":"3月23日亚虹医药跌9.43%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621768117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621768117?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:35","pubTimestamp":1774254955,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日亚虹医药跌9.43%，收盘报12.39元，换手率5.61%，成交量24.43万手，成交额3.14亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。中航优选领航混合发起A目前规模为0.47亿元，最新净值1.5704，较上一交易日下跌2.75%，近一年上涨33.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621776856","title":"亚虹医药跌9.43%，太平洋五日前给出“买入”评级，目标价17.91元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621776856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621776856?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:35","pubTimestamp":1774254947,"startTime":"0","endTime":"0","summary":"今日亚虹医药跌9.43%，收盘报12.39元。2026年3月18日，太平洋研究员周豫,戎晓婕发布了对亚虹医药的研报《APL-1702获批上市，开启商业化新阶段》，该研报对亚虹医药给出“买入”评级，认为其目标价为17.91元，研报发布时股价为14.50元，预期涨幅为23.52%。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为73.22%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的唐寅灏。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","601099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618181153","title":"3月12日亚虹医药跌5.67%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618181153","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618181153?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:21","pubTimestamp":1773303698,"startTime":"0","endTime":"0","summary":"证券之星消息，3月12日亚虹医药跌5.67%，收盘报15.8元，换手率10.25%，成交量44.67万手，成交额7.05亿元。重仓亚虹医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。中航优选领航混合发起A目前规模为0.47亿元，最新净值1.6795，较上一交易日下跌1.74%，近一年上涨46.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200026010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618943131","title":"华鑫证券：给予亚虹医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2618943131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618943131?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:56","pubTimestamp":1773222969,"startTime":"0","endTime":"0","summary":"华鑫证券有限责任公司胡博新,吴景欢近期对亚虹医药进行研究并发布了研究报告《公司事件点评报告：核心品种APL-1702获批上市，公司发展迈入新阶段》，给予亚虹医药买入评级。考虑核心大品种希维她获批上市，销售放量后有望大幅增厚公司营收，叠加仿制药收入持续增长，维持“买入”投资评级。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100029922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618164635","title":"3月9日亚虹医药涨5.24%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618164635","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618164635?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:20","pubTimestamp":1773044407,"startTime":"0","endTime":"0","summary":"证券之星消息，3月9日亚虹医药涨5.24%创60日新高，收盘报17.66元，换手率14.15%，成交量61.66万手，成交额10.56亿元。重仓亚虹医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。中航优选领航混合发起A目前规模为0.47亿元，最新净值1.6429，较上一交易日上涨6.61%，近一年上涨43.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900020738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617682920","title":"亚虹医药(688176.SH)：希维她®相关生产、进口时间及程序存在不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2617682920","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617682920?lang=zh_cn&edition=full","pubTime":"2026-03-06 19:39","pubTimestamp":1772797170,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)公告称，希维她®为境外生产药品，在公司取得该产品的上市批准后，方可开始逐步进行境外委托生产、进口、销售等环节。相关生产、进口的时间及程序均存在一定的不确定性，容易受到政策环境等多种因素的影响。产品未来的销售主要产生于医院和双通道药房，前述市场的进入需要履行相关审核程序，且容易受到政策环境、市场需求及市场竞争等多种因素的影响，最终能否实现商业目标存在一定的不确定性","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617686392","title":"3月6日亚虹医药（688176）龙虎榜数据：北向资金净买入2557.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617686392","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617686392?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:18","pubTimestamp":1772788718,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年3月6日公布的交易公开信息显示，亚虹医药因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券，有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年3月6日收盘，亚虹医药报收于16.78元，上涨20.03%，涨停，换手率14.02%，成交量61.08万手，成交额9.78亿元。从龙虎榜公布的当日买卖数据来看，北向资金合计净买入2557.14万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600028027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617052535","title":"异动快报：亚虹医药-U（688176）3月6日10点7分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2617052535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617052535?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:10","pubTimestamp":1772763055,"startTime":"0","endTime":"0","summary":"证券之星3月6日盘中消息，10点7分亚虹医药-U（688176）触及涨停板。其所属行业化学制药目前上涨。领涨股为亚虹医药。该股为创新药，医药概念热股，当日创新药概念上涨2.37%，医药概念上涨1.86%。3月5日的资金流向数据方面，主力资金净流出861.17万元，占总成交额1.16%，游资资金净流出2634.56万元，占总成交额3.54%，散户资金净流入3495.73万元，占总成交额4.7%。近5日资金流向一览见下表：亚虹医药-U主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600010510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779290987899,"stockEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0893},{"period":"3month","weight":0.0551},{"period":"6month","weight":0.264},{"period":"1year","weight":0.6268},{"period":"ytd","weight":0.0982}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0292},{"period":"3month","weight":0.0214},{"period":"6month","weight":0.0607},{"period":"1year","weight":0.2381},{"period":"ytd","weight":0.0506}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26290人(较上一季度增加9.18%)","perCapita":"16572股","listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","registeredCapital":"57117万元","survey":" 江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域专科创新药的研发、生产和销售。公司的主要产品是APL-1702(希维她®)、APL-2302、APL-2501、AT-018、AT-021、APL-1706(海克威®)、APLD-2304、APL-1202、APL-2401、APL-1202、APL-1401、APL-2301。","listedPrice":22.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药-U(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药-U(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药-U,688176,亚虹医药-U股票,亚虹医药-U股票老虎,亚虹医药-U股票老虎国际,亚虹医药-U行情,亚虹医药-U股票行情,亚虹医药-U股价,亚虹医药-U股市,亚虹医药-U股票价格,亚虹医药-U股票交易,亚虹医药-U股票购买,亚虹医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药-U(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药-U(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}